The glucocorticoid receptor agonistic modulators CpdX and CpdX-D3 do not generate the debilitating effects of synthetic glucocorticoids [Medical Sciences]
Seventy years after the discovery of their anti-inflammatory properties, glucocorticoids (GCs) remain the mainstay treatment for major allergic and inflammatory disorders, such as atopic dermatitis, asthma, rheumatoid arthritis, colitis, and conjunctivitis, among others. However, their long-term therapeutical administration is limited by major debilitating side effects, e.g., skin atrophy, osteoporosis, Addison-like...
Source: Proceedings of the National Academy of Sciences - Category: Science Authors: Guoqiang Hua, Naimah Zein, Laetitia Paulen, Pierre Chambon Tags: PNAS Plus Source Type: research
More News: Academies | Addison's Disease | Allergy & Immunology | Arthritis | Asthma | Conjunctivitis | Dermatitis | Dermatology | Orthopaedics | Osteoporosis | Rheumatoid Arthritis | Rheumatology | Science | Skin